DUBLIN, May 24, 2023 /PRNewswire/ — The “Small-Cell-Lung Cancer in the United States, 2022-2042: Cancer Populations USA Report and Data Dashboard” report has been added to ResearchAndMarkets.com’s offering.

The Cancer Populations USA report series provides detailed descriptive epidemiology estimates, forecast out to 20 years, and insights, to support clinical trial design and enrolment, market opportunity assessment and post-marketing authorization activities.

Cancer Populations USA is unique in routinely stratifying key cancer populations by race and ethnicity, which can be used to assess the representativeness of clinical trial populations, as well as identify areas of health inequities between different race-ethnicity population groups.

All estimates in this report are based on nationally representative datasets, such as population-based cancer registries, large epidemiological studies and published national population forecasts. Modelled estimates are based on the best practice industry methods to estimate recurrence events and, where required, make imputations and extrapolations.

We provide estimates for the year 2022 and forecast estimates to 2032 and 2042 in the main body of this report. Annualized forecast estimates are provided in supplementary tables at the end of the report, and also in the accompanying data dashboard, if purchased.

Stratification of incident cases by stage is based on the scheme specified by the American Joint Committee on Cancer (AJCC) 8th edition. Due to small numbers, some stage groups have been aggregated in this report. Wherever possible, this has been into meaningful groupings based on recommended clinical practice (NCCN, 2023).

In this report on small-cell-lung cancer (SCLC), forecast estimates are provided of incident cases by stage, age and gender, race-ethnicity, anatomical subsite, and PD-1/PD-L1 status. Additionally, the author forecasts those cases each year that become eligible for 1st line treatment for advanced…